Orchid Pharma is challenging a ₹0.17 crore tax demand order, stating it's an old issue resolved by its insolvency plan. Management expects no material financial impact.

Orchid Pharma Challenges ₹0.17 Crore Tax Demand

Orchid Pharma Limited has received an order from the Additional Commissioner of Central Tax, Chennai-Outer Commissionerate, demanding ₹0.17 crore (₹167.08 lakh) plus applicable interest. The demand relates to an allegedly erroneously sanctioned refund.

Reader Takeaway: Company appeals tax demand; management expects no material financial impact.

What just happened

An order has been issued by the Additional Commissioner of Central Tax, Chennai-Outer Commissionerate, demanding recovery of ₹0.17 crore (₹167.08 lakh) plus interest. This demand is based on an earlier refund that the tax authority claims was erroneously sanctioned under Section 11A of the Central Excise Act, 1944.

Why this matters

While the amount is relatively small, any tax demand can create uncertainty for investors. Orchid Pharma's proactive stance in appealing the order and its management's assertion of no material impact are key points for shareholders to consider.

The backstory

The company highlights that the tax demand pertains to a period before its Corporate Insolvency Resolution Process (CIRP). Following its acquisition under a Resolution Plan sanctioned by the National Company Law Tribunal (NCLT), management believes existing liabilities from that pre-CIRP period are covered.

What changes now

Orchid Pharma plans to file an appeal with the appropriate appellate authority. The company believes the order is unjustified and unsustainable. Management's position is that the resolution plan has already addressed such historical liabilities.

Risks to watch

The primary risk is the outcome of the appeal. If the appeal is unsuccessful, the company may have to pay the demand plus interest. However, management's confidence in the resolution plan covering this liability mitigates some of this risk.

Peer comparison

Tax disputes are common in the pharmaceutical industry. Companies often face such demands related to retrospective interpretations of tax laws or past refund issues. How Orchid Pharma navigates this appeal will be closely watched.

Context metrics (time-bound)

The order from the tax authority is dated June 09, 2026. The demand is for ₹0.17 crore (₹167.08 lakh).

What to track next

Investors should monitor the company's progress in filing the appeal and any subsequent orders from the appellate authority. Management's assessment of the financial impact will also be crucial.